CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Association of Cardiovascular Disease With Respiratory Disease Dapagliflozin for treating chronic heart failure with reduced ejection fraction Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment

Review Articlev.10(8); 2021 Aug

JOURNAL:Cells. Article Link

Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis

W Masson, A Lavalle-Cobo, JP Nogueira et al. Keywords: SGLT2-i; epicardial adipose tissue

Full Text PDF